In which country is tucatinib available?

Tucatinib is an oral targeted therapy drug, mainly used for the treatment of HER2-positive breast cancer. It is a serine/threonine protein kinase inhibitor that inhibits the growth and spread of tumor cells by inhibiting the signaling pathway caused by HER2 receptor activation. It was approved for marketing by the U.S. Food and Drug Administration (FDA) in April 2020, and was launched in Australia in August of the same year. In February 2021, the European Union approved its medical use. It is understood that the original drug Tucatinib has not yet been launched in China, so it has not entered the scope of domestic medical insurance. Patients in need cannot yet purchase this drug in pharmacies or hospitals.